Moreover, mice with an ovarian tumor subjected to treatment targeting tumor-derived UBR5, concurrently with anti-PD-1 mAbs, responded to the therapy, whereas mice treated only with anti-PD-1 agents did not [106]. This evidence concerns the gene PDCD1 and neoplasm.